CLINICAL TRIAL: OGF & GEMCITABINE: NOVEL TREATMENT FOR PANCREATIC CANCER

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本方案的主要目的是评价OGF生物治疗和吉西他滨化疗联合的安全性和毒性。本研究的目的是测试OGF和吉西他滨联合治疗的安全性和毒性。此外，还将评价OGF生物治疗和吉西他滨化疗与标准化疗（吉西他滨）单独治疗相比对晚期胰腺癌患者至疾病进展时间的疗效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this protocol is to evaluate the safety and toxicity of the combination of OGF biotherapy and gemcitabine chemotherapy. The purpose of this objective is to test the safety and toxicity of the combination treatments OGF and gemcitabine. Additionally , the efficacy of OGF biotherapy and gemcitabine chemotherapy on time to progression of disease in patients with advanced pancreatic cancer compared with those treated with standard chemotherapy (gemcitabine) alone will be evaluated.